Bioeconomy Capital is a biotechnology investment firm. The primary focus of Bioeconomy Captial is the industrialization of early stage biotechnology companies operating within the bioeconomy making products such as materials, chemicals, and enzymes.
Completion of Bioeconomy Fund 1
On January 1, 2017 Bioeconomy Capital completed their bioeconomy fund 1 investment portfolio of early stage biotechnology companies. Bioeconomy Capital invested a total of $8.3 million into 6 early stage biotechnology companies — Zymergen, Riffyn, Rooster Bio, Synthace, Arzeda, and Bellwether Bio.
Investments
Timeline
Completion of Bioeconomy Fund 1
On January 1, 2017 Bioeconomy Capital completed their bioeconomy fund 1 investment portfolio of early stage biotechnology companies. Bioeconomy Capital invested a total of $8.3 million into 6 early stage biotechnology companies — Zymergen, Riffyn, Rooster Bio, Synthace, Arzeda, and Bellwether Bio.
People
Rik Wehbring
Founder & managing director (San Francisco)
Rob Carlson
Founder & managing director (Seattle)
Tim Fell
Employee
Tim Gardner
Employee
Further reading
GBS 2018: Bioeconomy leaders foster shift to sustainable industry production
BIOCOM AG
News article
Xconomy: Seattle Area Had a Middling 2017 for Venture Investment, Fundraising
Benjamin Romano
News article
Documentaries, videos and podcasts
Companies